GlassScriptPhysician profile
Julie A Cox
NPI 1063857233
$1,601.77
in general payments reported to CMS, 2019-2025
26 companies · $593 in 2025
The $593 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.74 · 2022: $119 · 2023: $127 · 2024: $722 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $324.53 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $214.40 | 2023-2024 | Cobenfy, Camzyos |
| Alkermes, INC. | $106.01 | 2024-2025 | Lybalvi, Aristada |
| Idorsia Pharmaceuticals US INC | $105.95 | 2022-2023 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $97.50 | 2025 | |
| Janssen Pharmaceuticals, INC | $96.76 | 2024-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $79.98 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $65.46 | 2024-2025 | Ingrezza |
| Abbvie INC. | $58.04 | 2021-2022 | |
| Harmony Biosciences LLC | $52.56 | 2025 | |
| Corium, LLC | $51.31 | 2024-2025 | Azstarys |
| Indivior INC. | $51.17 | 2024-2025 | Sublocade |
| Amgen INC. | $29.64 | 2023 | Prolia, Evenity |
| Noven Therapeutics, LLC | $29.52 | 2024-2025 | Xelstrym, Secuado |
| Sage Therapeutics, LLC | $29.03 | 2025 | Zurzuvae |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28.27 | 2023 | Mounjaro, Basaglar |
| Ironshore Pharmaceuticals INC. | $27.07 | 2024 | |
| Almatica Pharma LLC | $22.40 | 2024 | Loreev Xr |
| Bayer Healthcare Pharmaceuticals INC. | $20.10 | 2023 | |
| Axsome Therapeutics, INC. | $18.04 | 2024 | Auvelity |
| Daiichi Sankyo INC. | $17.97 | 2023 | Injectafer |
| Tris Pharma INC | $17.69 | 2025 | Dyanavel Xr |
| Acadia Pharmaceuticals INC | $15.54 | 2025 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $15.06 | 2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $14.27 | 2025 | Uzedy |
| Pfizer INC. | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.